| Stage | LLY | % of rev | CPRX | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $24.4B | 100.00% | $149M | 100.00% | LLY ×163.31 |
| Gross profit | $20.5B | 83.88% | $135M | 90.31% | CPRX +6.4pp |
| Operating income | $8.6B | 35.28% | $73M | 49.02% | CPRX +13.7pp |
| Pre-tax income | $8.4B | 34.46% | $84M | 56.38% | CPRX +21.9pp |
| Net income | $6.5B | 26.44% | $64M | 42.66% | CPRX +16.2pp |
| Stage | LLY | CPRX | Gap · A − B |
|---|---|---|---|
| Revenue | $24.4B100.00% | $149M100.00% | LLY ×163.31 |
| Gross profit | 83.88%$20.5B | 90.31%$135M | CPRX +6.4pp |
| Operating income | 35.28%$8.6B | 49.02%$73M | CPRX +13.7pp |
| Pre-tax income | 34.46%$8.4B | 56.38%$84M | CPRX +21.9pp |
| Net income | 26.44%$6.5B | 42.66%$64M | CPRX +16.2pp |
No disclosed counterparties: CPRX.
None